The invention refers to a pharmaceutical compound including an antibody that specifically binds acrylonitrile methylene acrylonitrile / kexina (PCSK9),a. A method of treating a disease or condition in which the characterization or activity of adrenaline causes an impact of methyleneiminase / kexina type 9 (PCSK9) by using specific PCSK9 antibody or antigen binding fragments, preferably increased use 3-hydroxy-3-methyl-glucose-coal reduction inhibitorCtasa (HMG-CoA reductase). The invention also relates to a specific polychlorinated biphenyl antibody or a binding fragment of its antigen, which is used for treating diseases or diseases affected by the performance or activity of polychlorinated biphenyls. The invention also relates to finished products including packaging materialsSpecific polychlorinated biphenyl antibodies or fragments bound to polychlorinated biphenyl antigensThere is also a label or instruction to indicate which groups of patients can be treated with this antibody or fragment, which groups of patients should not be treated with this antibody or fragment, and what dose system should be used. The invention also relates to a method for testing the effectiveness of a specific polychlorinated biphenyl9 antibody or its antigen binding fragment to treat certain diseases or diseases and to treat a specific patient group.La presente invención se refiere a Composiciones farmacéuticas que comprenden un anticuerpo que se une específicamente a la proproteína convertasa subtilisina/kexina tipo 9 humana (PCSK9), a métodos para tratar enfermedades o afecciones en las que la expresión o actividad de la proproteína convertasa subtilisina/kexina tipo 9 (PCSK9) ocasiona un impacto mediante la administración de anticuerpos específicos para PCSK9 o fragmentos de unión al antígeno de los mismos y preferiblemente mediante la administración adicional de un inhibidor de 3-hidroxi-3-metil-glutaril-CoA reductasa (HMG-CoA reductasa). La presente invención se refiere adicionalm
